Siolta Therapeutics
Early stage, venture-backed biotech company focused on developing therapeutic microbial consortia to prevent and treat inflammatory diseases.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor | €0.0 | round |
| investor investor | €0.0 | round | |
| investor investor investor | €0.0 | round | |
| investor investor investor investor investor | €0.0 | round | |
| investor investor | €0.0 | round | |
* | $12.0m Valuation: $150m | Series C | |
| Total Funding | 000k | ||
Related Content
Siolta Therapeutics is a clinical-stage biopharmaceutical company that develops live biotherapeutic products (LBPs) to prevent and treat diseases by modulating the human microbiome.
The company's platform integrates clinical data, bioinformatics, and microbial science to create precisely defined consortia of microbes. Siolta's primary focus is on the developing infant gut microbiome and its influence on immune system programming, a critical area for preventing allergic and inflammatory conditions.
By targeting the maternal-infant axis, Siolta aims to deliver therapeutic interventions that can establish a healthy microbiome from the earliest stages of life. The company's lead product, STMC-103, is a mixed-species LBP in clinical development for the prevention of atopic diseases such as eczema and asthma.
Siolta Therapeutics has secured substantial funding through Series B and C financing rounds, enabling the advancement of its clinical programs. The company also engages in strategic collaborations to further its research and development efforts.
Keywords: biopharmaceutical, microbiome, live biotherapeutic products, immunology, clinical-stage, infant health, atopic disease, microbial science, bioinformatics, gut health